| Literature DB >> 29190948 |
Tao Yang1,2, Wenhui Shi3, Zukereguli Wumaierniyazi1, Lianlian Shan1, Weiwei Miao1, Guizhen Wu2, Bin Zhou1, Abdryim Yusup4, Halmurat Upur4, Ainiwaer Aikemu1,2.
Abstract
Previous research has demonstrated the anti-tumor properties of Abnormal Savda Munziq (ASMq), a traditional Uyghur compound herbal medicine. The effects of ASMq on cervical carcinomas in U27 tumor-bearing mice is investigated, the effect of adding Fluorouracil (5-FU) is also assessed in this paper. The results demonstrate that ASMq and 5-FU significantly inhibited the proliferation of U27 cells in a time-dependent and dose-dependent manner. Evaluating the interactions between ASMq and 5-FU on U27 cell growth yields a combination index (CI) < 1 in different time periods, suggesting a synergistic effect between the two drugs in vitro. Nuclear magnetic resonance (NMR) analysis demonstrates that ASMq can inhibit enhanced lipid metabolism in tumor mice, enhance the glutamine content, promote lymphocyte and macrophage proliferation, and increase tumor necrosis factor(TNF-α) and interleukin(IL) production, which can enhance the effect of 5-FU on the inhibition of tumors. Also ASMq can reduce the content of ALT and AST in serum. Increased SOD, GSH-Px, and decreased the content of MDA in liver tissue. ASMq has a synergistic effect on liver and tumor pathology, as well as tumor inhibition rate. In addition, ASMq can also enhance the body's antioxidant capacity and improve the body's metabolism, and reduce 5-FU's toxic side effects.Entities:
Keywords: 5-FU; Abnormal Savda Munziq; cervical cancer
Year: 2017 PMID: 29190948 PMCID: PMC5696214 DOI: 10.18632/oncotarget.21563
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Inhibitory effect of ASMq or/and 5-fluorouracil on the growth of U27 cells
(A) Growth inhibition rate of U27 cells following 24, 48 or 72 h treatment with increasing concentrations of 5-fluorouracil. (B) Growth inhibition rate of U27 cells following 24, 48 or 72 h treatment with increasing concentrations of Abnormal Savda Munziq (ASMq). (C) Growth inhibition rate of U27 cells following 24, 48 or 72 h treatment with increasing concentrations of 5-fluorouracil combined with Abnormal Savda Munziq (ASMq).
Analysis of the interaction between the inhibition effect of ASMq in combination with 5-fluorouracil on cell growth by combination index
| Times(h) | Combination index | |
|---|---|---|
| 24 | 0.7041±0.1112 | <0.05 |
| 48 | 0.6141±0.1041 | <0.05 |
| 72 | 0.5243±0.0914 | <0.05 |
Inhibitory effect of ASMq on the growth of transplanted cervical cancer tumors in mice when combined with 5-FU ()
| Group | Dosage /(g/kg) | Start animals/ end animals | Tumor weight /(mg) | Inhibition rate /% |
|---|---|---|---|---|
| Control | - | 10/10 | 0.000±0.000 | - |
| Model | - | 10/10 | 2682.5875±256.7856b | - |
| 5-FU | 0.03 | 10/10 | 899.0875±282.6327a | 66.48 |
| 5-FU +ASMq.H | 8 | 10/10 | 558.7875±342.0630ab | 79.17 |
| 5-FU +ASMq.M | 4 | 10/10 | 278.2875±153.0699ab | 89.63 |
| 5-FU +ASMq.L | 2 | 10/10 | 846.8750±372.0095a | 68.43 |
VS. Model group, aP<0.05;VS. 5-FU group, bP<0.05.
Figure 2Tumor growth curve
Figure 3600 MHz 1H-NMR Spectra of serum
(A) control group; (B) model group; (C) 5-FU group; (D) ASMq.L group; (E) ASMq.M group; (F) ASMq.H group.
Figure 4OPLS-DA 3D plots of 1H-NMR spectra
control group; model group; 5-FU group; ASMq.L group; ASMq.M group; ASMq.H group.
Otherness metabolites of mice serum in each group
| Order number | Metabolite | Chemical shift(ppm) | Assignment |
|---|---|---|---|
| 1 | Lipids | 0.85(m) | CH3(CH2)n |
| 2 | Isoleucine | 0.93(t), 1.00(d) | δ-CH3, β-CH3 |
| 3 | Leucine | 0.97(d) | δ-CH3 |
| 4 | Valine | 1.03(d) | α-CH2 |
| 5 | β-Hydroxy butyric acid | 1.19(d) | γ- CH3 |
| 6 | Lactate | 1.32(d), 4.11(q) | CH3, CH |
| 7 | Alanine | 1.46(d) | CH3, α-CH |
| 8 | Acetate | 1.91(s) | CH3 |
| 9 | Glycoprotein | 2.03(s) | NHCO-CH3 |
| 10 | Acetone | 2.22(s) | CH3 |
| 11 | Pyruvate | 2.36(s) | CH3 |
| 12 | Carnitine | 2.44(dd) | CH2(COO) |
| 13 | Citrate | 2.52(d), 2.66(d) | CH2, CH2 |
| 14 | Glutamine | 2.13(m), 3.76(m), 3.69(t) | halfβ-CH2, α-CH |
| 15 | Glycine | 3.56(s) | CH2 |
| 16 | Tyrosine | 6.89(d), 7.18(d) | α-CH, H3/H5, H2/H6 |
| 17 | Phenylalanine | 7.32(m), 7.42(m) | H2/H6, H4, H3/H5 |
| 18 | 1-methylhistidine | 7.05(s), 7.78(s) | H4, H2 |
| 19 | a-glucose | 3.53(dd), 3.72(d), 5.23(d), 3.83(m) | C-H2, halfCH2-CH6, C-H1, C-H6 |
| 20 | β-glucose | 3.23(dd), 3.40(t), 3.47(ddd), 4.64(d) | C-H4, C-H5, halfCH2-CH6, C-H1, C-H3 |
| 21 | LDL | 1.26(m) | CH3CH2(CH2)n |
| 22 | Unsaturated lipid | 5.28(m) | CHCH2CH2 |
| 23 | Creatine | 3.03(s), 3.93(s) | CH3, CH2 |
s is singlet; d is doublet; t is triplet; q is quartet; m is multiplet; dd is doublet of doublets; ddd is doublet of doublets of doublets.
Difference correlation coefficients of otherness metabolites in mice serum
| Order number | Metabolite | Normal control group compared with the model group | model group compared with the 5-FU group | model group compared with the ASMq.L group | model group compared with the ASMq.M group | model group compared with the ASMq.H group | 5-FU group compared with the ASMq.L group | 5-FU group compared with the ASMq.M group | 5-FU group compared with the ASMq.H group | |
|---|---|---|---|---|---|---|---|---|---|---|
| R2X | 0.79 | 0.7 | 0.84 | 0.78 | 0.71 | 0.85 | 0.74 | 0.7 | ||
| Q2 | 0.34 | 0.3 | 0.86 | 0.83 | 0.51 | 0.79 | 0.67 | 0.6 | ||
| 1 | Lipids | 0.62 | -0.74 | -0.71 | -0.65 | -0.66 | -0.81 | |||
| 2 | Isoleucine | -0.6 | 0.74 | 0.62 | ||||||
| 3 | Leucine | 0.81 | 0.76 | |||||||
| 4 | Valine | -0.71 | 0.87 | 0.66 | ||||||
| 5 | β-Hydroxy butyric acid | 0.74 | 0.66 | 0.67 | ||||||
| 6 | Lactate | -0.72 | -0.81 | |||||||
| 7 | Alanine | -0.63 | 0.63 | 0.67 | 0.61 | 0.72 | ||||
| 8 | Acetate | -0.73 | 0.74 | 0.89 | ||||||
| 9 | Glycoprotein | 0.63 | -0.81 | |||||||
| 10 | Acetone | 0.6 | -0.72 | -0.92 | -0.72 | -0.76 | -0.96 | -0.82 | ||
| 11 | Pyruvate | -0.62 | 0.73 | 0.94 | 0.73 | |||||
| 12 | Carnitine | 0.72 | -0.68 | |||||||
| 13 | Citrate | -0.73 | 0.77 | 0.58 | 0.65 | |||||
| 14 | Glutamine | -0.75 | 0.67 | 0.62 | 0.67 | |||||
| 15 | Glycine | -0.59 | 0.8 | 0.85 | 0.88 | |||||
| 16 | Tyrosine | 0.72 | -0.81 | 0.84 | ||||||
| 17 | Phenylalanine | 0.8 | 0.58 | 0.71 | ||||||
| 18 | 1-methylhistidine | -0.77 | 0.59 | 0.86 | 0.62 | 0.65 | ||||
| 19 | a-glucose | 0.6 | 0.69 | 0.73 | 0.63 | |||||
| 20 | β-glucose | -0.64 | 0.71 | 0.77 | 0.75 | 0.67 | ||||
| 21 | LDL | 0.65 | -0.6 | -0.91 | -0.63 | -0.95 | -0.85 | -0.87 | ||
| 22 | Unsaturated lipid | 0.63 | -0.63 | -0.72 | -0.63 | -0.69 | -0.65 | -0.6 | ||
| 23 | Creatine | -0.74 | -0.6 | 0.62 | 0.6 | 0.72 | 0.73 | 0.65 |
Effect of 5-FU combined with ASMq on serum IL-2, TNF-α content of U27 bearing mice (, n=10)
| Group | Dosage (g/kg) | IL-2 (U/mg prot) | TNF-α (pg/ml) | |
|---|---|---|---|---|
| ASMq | 5-FU | |||
| Control | - | - | 16.9813±0.8103 | 18.0654±1.2321 |
| Model | - | - | 14.9947±0.7124ac | 15.6427±0.9671ac |
| 5-FU | - | 0.03 | 13.7231±0.7123ab | 14.8337±1.2120ab |
| 5-FU+ASMq.H | 8 | 0.03 | 19.2434±1.0271abc | 21.9538±0.9837abc |
| 5-FU+ASMq.M | 4 | 0.03 | 22.9654±1.2587abc | 26.9731±0.7454abc |
| 5-FU+ASMq.L | 2 | 0.03 | 17.8847±0.8124bc | 18.7351±1.3423bc |
VS control group, aP<0.05; VS model group, bP<0.05, VS 5-FU group, cP<0.05.
The effects of 5-FU combined with Abnormal Savda Munziq on the expression of ALT, AST in mice serum ()
| Group | Dosage (g/kg) | ALT (pg/ml) | AST (pg/ml) | |
|---|---|---|---|---|
| ASMq | 5-FU | |||
| Control | - | - | 83.758±1.103 | 47.832±0.601 |
| Model | - | - | 79.875±3.114c | 47.980±0.521c |
| 5-FU | - | 0.03 | 506.864±22.061ab | 237.145±6.424ab |
| 5-FU+ASMq.H | 8 | 0.03 | 198.132±14.451abc | 147.173±7.455abc |
| 5-FU+ASMq.M | 4 | 0.03 | 121.165±14.176abc | 80.724±1.453abc |
| 5-FU+ASMq.L | 2 | 0.03 | 397.794±35.407abc | 217.425±8.147abc |
VS control group, aP<0.05;VS model group, bP<0.05; VS 5-FU group, cP<0.05.
Effect of 5-FU combined with ASMq on the liver of mice bearing U27 tumor ()
| Group | Dosage (g/kg) | SOD (U/mg prot) | GSH-Px (U/mg prot) | MDA (nmol/mg prot) | |
|---|---|---|---|---|---|
| ASMq | 5-FU | ||||
| Control | - | - | 90.678±1.786 | 134.432±10.145 | 5.227±0.124 |
| Model | - | - | 73.378±2.446 ac | 101.045±4.123ac | 9.996±0.785ac |
| 5-FU | - | 0.03 | 57.456±3.651 ab | 91.147±2.229ab | 13.457±0.716ab |
| 5-FU+ASMq.H | 8 | 0.03 | 101.345±3.245 abc | 116.021±2.476abc | 6.978±0.564abc |
| 5-FU+ASMq.M | 4 | 0.03 | 120.154±2.667 abc | 149.554±3.174abc | 5.013±0.382bc |
| 5-FU+ASMq.L | 2 | 0.03 | 100.045±4.4786abc | 106.124±2.313abc | 7.453±0.768abc |
Note: VS control group, aP<0.05;VS model group, bP<0.05; VS 5-FU group, cP<0.05.
Figure 5Liver pathology examination
Figure 6Tumor pathology examination